{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:08:27Z","timestamp":1788318507466,"version":"build-2803163510"},"reference-count":28,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,12]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Children receiving BuFlu for nonmalignant conditions experienced less toxicity than those receiving BuCy, but survival was comparable. Children with malignancy had shorter postrelapse survival with BuFlu than BuCy; transplant-related mortality and relapse were similar.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018016956","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T12:00:13Z","timestamp":1527595213000},"page":"1198-1206","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-8817","authenticated-orcid":false,"given":"Andrew C.","family":"Harris","sequence":"first","affiliation":[{"name":"Pediatric Blood and Marrow Transplant Program, Univeristy of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap J.","family":"Boelens","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, Princess Maximax Center, Utrecht, The Netherlands;"},{"name":"Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-8037","authenticated-orcid":false,"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"},{"name":"Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5627-4102","authenticated-orcid":false,"given":"Mingwei","family":"Fei","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-0887","authenticated-orcid":false,"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago School of Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3952","authenticated-orcid":false,"given":"Christopher","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco Medical Center, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydar","family":"Frangoul","sequence":"additional","affiliation":[{"name":"The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-6797","authenticated-orcid":false,"given":"Cesar","family":"Freytes","sequence":"additional","affiliation":[{"name":"Texas Transplant Institute, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-5994","authenticated-orcid":false,"given":"Sanghee","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5607","authenticated-orcid":false,"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Loren","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[{"name":"Penn State Hershey Medical Center, Hershey, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-6162","authenticated-orcid":false,"given":"Tracey","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children\u2019s Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-5286","authenticated-orcid":false,"given":"Kirsten","family":"Williams","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-0800","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"issue":"4","key":"2019111618582658800_B1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.23533","article-title":"Hepatobiliary complications of hematopoietic cell transplantation, 40 years on","volume":"51","author":"McDonald","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"2019111618582658800_B2","first-page":"467","article-title":"Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome","volume":"7","author":"Ozkaynak","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111618582658800_B3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00007890-199310000-00020","article-title":"Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications","volume":"56","author":"Sencer","year":"1993","journal-title":"Transplantation"},{"issue":"2","key":"2019111618582658800_B4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2019111618582658800_B5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111618582658800_B6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","article-title":"New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2","volume":"40","author":"Chae","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111618582658800_B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-6-15","article-title":"Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study","volume":"6","author":"Liu","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2019111618582658800_B8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111618582658800_B9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111618582658800_B10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111618582658800_B11","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111618582658800_B12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111618582658800_B13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"2","key":"2019111618582658800_B14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111618582658800_B15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clml.2014.04.006","article-title":"Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen","volume":"14","author":"Fedele","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111618582658800_B16","first-page":"12064","article-title":"Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis","volume":"8","author":"Lei","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"15","key":"2019111618582658800_B17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111618582658800_B18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111618582658800_B19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2014.03.028","article-title":"Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation","volume":"20","author":"Shah","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111618582658800_B20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bbmt.2017.05.011","article-title":"Personalized prognostic risk score for long-term survival for children with acute leukemia after allogeneic transplantation","volume":"23","author":"Bitan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111618582658800_B21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children\u2019s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children\u2019s oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111618582658800_B22","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/sj.leu.2403925","article-title":"Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children\u2019s Cancer Group: CCG 251, CCG 213 and CCG 2891","volume":"19","author":"Smith","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2019111618582658800_B23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.12142","article-title":"Advances in predicting acute GVHD","volume":"160","author":"Harris","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111618582658800_B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111618582658800_B25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","article-title":"High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients","volume":"20","author":"Ljungman","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111618582658800_B26","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111618582658800_B27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-3-36","article-title":"Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia","volume":"3","author":"Pidala","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2019111618582658800_B28","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/11\/1198\/881976\/advances016956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/11\/1198\/881976\/advances016956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T18:58:38Z","timestamp":1573930718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/11\/1198\/16070\/Comparison-of-pediatric-allogeneic-transplant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018016956","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]}}}